DPP-4 inhibitors for treating diabetes in patients showing contraindication against metformin therapy

摘要

Disclosed herein is the use of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, which is a DPP-4 inhibitor, or a pharmaceutically acceptable salt thereof, for preparing a medicament for oral administration for treating and/or preventing of metabolic diseases in patients for whom metformin therapy is inappropriate due to contraindication against metformin. Said medicament may be used in the treatment and/or prevention of type 2 diabetes mellitus in patients with at least one contraindication selected from: renal disease, renal impairment or renal dysfunction; dehydration; unstable or acute congestive heart failure; acute or chromic metabolic acidosis; and hereditary galactose intolerance. The disclosure also relates to the use of said DPP-4 inhibitor in combination with one or more further active substances selected from sulphonylureas, thiazolidinedones, glinides, alpha-glucosidase blockers, GLP-1 and GLP-1 analogues, and insulin and insulin analogues.